Related Experiment Videos
Endocrine active agents: implications of adverse and non-adverse changes
Paul M D Foster1, Barry S McIntyre
1CIIT Centers for Health Research, Research Triangle Park, North Carolina 27709-2137, USA. foster@ciit.org
Toxicologic Pathology
|March 15, 2002
Summary
Developing effective endocrine disruptor testing requires comprehensive data, including dose, response, and species life stage. In vitro assays and short-term in vivo studies alone are insufficient for accurate risk assessment.
Area of Science:
- Environmental Toxicology
- Endocrine Disruption
- Chemical Risk Assessment
Background:
- The US Environmental Protection Agency (EPA) is developing screening and testing methods for endocrine-disrupting chemicals.
- There is significant interest in how this information will be used for risk assessment, regulation, and public information.
- Current methods, including in vitro assays and short-term in vivo studies, have limitations in accurately assessing endocrine disruptor risks.
Purpose of the Study:
- To critically evaluate the utility and limitations of current and proposed testing methodologies for endocrine disruptors.
- To highlight the importance of considering dose, response, and life stage in endocrine disruptor assessment.
- To discuss the interpretation of new endpoints and the adequacy of existing study designs for risk assessment.
Main Methods:
- Review of in vitro receptor interaction assays and their limitations.
- Analysis of short-term in vivo studies (e.g., uterotrophic, Hershberger) and their interpretation.
- Evaluation of new endpoints in rodent testing (anogenital distance, developmental landmarks) and multigeneration studies.
Main Results:
- In vitro data alone is insufficient and can be misleading when high-quality in vivo data shows no adverse effects.
- Short-term in vivo studies in castrated animals indicate pharmacological potential, not necessarily adverse effects.
- New endpoints like anogenital distance require careful interpretation considering body weight and biological significance; permanent changes like retained nipples may indicate developmental toxicity.
Conclusions:
- Constructing lists of endocrine disruptors without detailed response, dose, and life stage information is of limited value.
- Current testing protocols, including multigeneration studies, may lack the power to detect low-incidence adverse effects.
- Accurate risk assessment requires comprehensive data from well-designed studies that consider all relevant factors, including permanent structural changes.